Synthesis and potent antifolate activity and cytotoxicity of B-ring deaza analogues of the nonpolyglutamatable dihydrofolate reductase inhibitor N(α)-(4-amino-4-deoxypteroyl)-N(δ)-hemiphthaloyl-L-ornithine (PT523)

Journal of Medicinal Chemistry

Volumn 41, Issue 26, 1998, Pages 5310-5319

  Rosowsky, Andre ^a   Wright, Joel E ^a   Vaidya, Chitra M ^a   Bader, Henry ^a   Forsch, Ronald A ^a   Mota, Clara E ^a   Pardo, Jorge ^a   Chen, Cindy S ^a   Chen, Ying Nan ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDROFOLATE REDUCTASE INHIBITOR; FOLIC ACID ANTAGONIST; NALPHA (4 AMINO 4 DEOXYPTEROYL) NDELTA HEMIPHTHALOYLORNITHINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CYTOTOXICITY; CYTOTOXICITY TEST; DRUG EFFECT; DRUG SCREENING; DRUG SYNTHESIS; HUMAN; HUMAN CELL;

ANTINEOPLASTIC AGENTS; DRUG SCREENING ASSAYS, ANTITUMOR; FOLIC ACID ANTAGONISTS; HUMANS; INHIBITORY CONCENTRATION 50; ORNITHINE; PTERINS; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 0032542248     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm980477+     Document Type: Article

References (50)

1. Rosowsky, A. Development of nonpolyglutamatable DHFR inhibitors. In Antifolate Drugs: Basic Research and Clinical Practice; Jackman, A. L., Ed.; Humana Press: Totowa, NJ; in press.
2. (a) Matsuoka, H.; Ohi, N.; Mihara, M.; Suzuki, H.; Miyamoto, K.; Maruyama, N.; Tsuji, K.; Kato, N.; Akimoto, T.; Takeda, Y.; Yano, K.; Kuroki, T. Antirheumatic agents: Novel methotrexate derivatives bearing a benzoxazine moiety. J. Med. Chem. 1997, 40, 105-111.
3. (b) Mihara, M.; Takagi, N.; Urakawa, K.; Moriya, Y.; Takeda, Y. Preventive effect of a novel antifolate, MX-68, in murine systemic lupus erythematosis (SLE). Int. J. Immunopharmacol. 1997, 19, 67-74.
4. Kokuryo, Y.; Kawata, K.; Nakatani, T.; Kugimiya, A.; Tamura, Y.; Kawada, K.; Matsumoto, M.; Suzuki, R.; Kuwabara, K.; Hori, Y.; Ohtani, M. Synthesis and evaluation of novel fluorinated methotrexate derivatives for application to rheumatoid arthritis treatment. J. Med. Chem. 1997, 40, 3280-3291.
5. Rosowsky, A.; Forsch, R.; Uren, J.; Wick, M.; Kumar, A. A.; Freisheim, J. H. Methotrexate analogues. 20. Replacement of glutamate by longer-chain amino diacids: Effects on dihydrofolate reductase inhibition, cytotoxicity, and in vivo antitumor activity. J. Med. Chem. 1983, 26, 1719-1724.
6. (a) Li, E.-W.; Lin, J. T.; Tong, W. P.; Trippett, T. M.; Brennan, M. F.; Bertino, J. R. Mechanisms of natural resistance to antifolates in human soft tissue sarcomas. Cancer Res. 1992, 52, 1434-1438.
7. (b) Li, W.-W.; Lin, J. T.; Schweitzer, B. I.; Tong, W. P.; Niedzwicki, D.; Bertino, J. R. Intrinsic resistance to methotrexate in human soft tissue sarcoma cell lines. Cancer Res. 1992, 52, 3908-3913.
8. (a) Pizzorno, G.; Chang, Y. M.; McGuire, J. J.; Bertino, J. R. Inherent resistance of human squamous carcinoma cell lines to methotrexate as a result of decreased polyglutamylation of this drug. Cancer Res. 1989, 49, 5275-5280.
9. (b) van Der Laan, B. F. A. M.; Jansen, G.; Kathmann, G. A. M.; Westerhof, G. R.; Schornagel, J. H.; Hordijk, G. J. In vitro activity of novel antifolates against human squamous carcinoma cell lines of the head and neck with inherent resistance to methotrexate. Int. J. Cancer 1992, 51, 909-914.
10. Barakat, R. R.; Li, W.-W.; Lovelace, C.; Bertino, J. R. Intrinsic resistance of cervical squamous cell carcinoma cell lines to methotrexate (MTX) as a result of decreased accumulation of intracellular MTX polyglutamates. Gynecol. Oncol. 1993, 51, 54-60.
11. (a) Whitehead, V. M.; Rosenblatt, D. S.; Vuchich, M.-J.; Shuster, J. J.; Witte, A.; Beaulieu, D. Accumulation of methotrexate and methotrexate polyglutamates in lymphoblasts at diagnosis of childhood acute lymphoblastic leukemia; A pilot prognostic factor analysis. Blood 1990, 76, 44-49.
12. (b) Lin, J. T.; Tong, W. P.; Trippett, T. M.; Nidzwiecki, D.; Tao, Y.; Tan, C.; Steinherz, P.; Schweitzer, I.; Bertino, J. R. Basis for natural resistance to methotrexate in human acute nonlymphocytic leukemia. Leukemia Res. 1991, 15, 1191-1196.
13. (c) Barredo, J. C.; Synold, T. W.; Laver, J.; Relling, M. V.; Pui, C.-C.; Priest, D. G.; Evans, W. E. Differences in constitutive and post-methotrexate folylpolyglutamate synthetase activity in B-lineage and T-lineage leukemia. Blood 1994, 84, 564-569.
14. (d) Galpin, A. M.; Schuetz, J. D.; Masson, E.; Yanishevski, Y.; Synold, T. E.; Barredo, J. C.; Pui, C.-H.; Relling, M. V.; Evans, W. E. Differences in folylpolyglutamate synthetase and dihydrofolate reductase expression in human B-lineage versus T-lineage leukemic lymphoblasts: mechanisms for lineage differences in methotrexate polyglutamation and cytotoxicity. Mol. Pharmacol. 1997, 52, 155-163.
15. α-(4-amino-4-deoxypteroyl)-L-ornithine derivatives: synthesis and in vitro antitumor activity. J. Med. Chem. 1988, 31, 1322-1337.
16. α-(4-amino-4-deoxypteroyl)-Nδ-hemiphthaloyl-L-ornithine. Pteridines 1989, 1, 91-98.
17. Westerhof, G. R.; Schornagel, J. H.; Kathmann, I.; Jackman, A. L.; Rosowsky, A.; Forsch, R. A.; Hynes, J. B.; Boyle, F. T.; Peters, G. J.; Pinedo, H. M.; Jansen, G. Carrier- and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes: correlates of molecular structure and biological activity. Mol. Pharmacol. 1995, 48, 459-471.
18. Rhee, M. S.; Galivan, J.; Wright, J. E.; Rosowsky, A. Biochemical studies on PT523, a potent nonpolyglutamatable antifolate, in cultured cells. Mol. Pharmacol. 1994, 45, 783-791.
19. Johnson, J. M.; Meiering, E. M.; Wright, J. E.; Pardo, J.; Rosowsky, A.; Wagner, G. NMR solution structure of the antitumor compound PT523 and NADPH in the ternary complex with human dihydrofolate reductase. Biochemistry 1997, 36, 4399-4411.
20. Cody, V.; Galitsky, N.; Luft, J. R.; Pangborn, W.; Rosowsky, A.; Blakley, R. L. Comparison of two independent crystal structures of human dihydrofolate reductase ternary complexes with reduced nicotinamide adenine dinucleotide phosphate and the very tight-binding inhibitor PT523. Biochemistry 1997, 36, 13897-13903.
21. (a) Klohs, W. D.; Steinkampf, R. W.; Besserer, J. A.; Fry, D. A. Cross resistance of pleiotropically drug resistant P388 leukemia cells to the lipophilic antifolates trimetrexate and BW301U. Cancer Lett. 1986, 31, 253-260.
22. (b) Ramu, N.; Ramu, A.; Cole, D. E.; Balis, F. M.; Poplack, D. G.; Pollard, H. B. Mechanism of acquired resistance to methotrexate in P388 cells and in their doxorubicin-resistant subline. Israel J. Med. Sci. 1988, 24, 477-482.
23. (c) Assaraf, Y. G.; Molina, A.; Schimke, R. T. Cross-resistance to the lipid-soluble antifolate trimetrexate in human carcinoma cells with the multidrug-resistant phenotype. J. Natl. Cancer Inst. 1989, 81, 290-294.
24. ω-hemiphthaloy-α,ω-diaminoalkanoic acid analogues of aminopterin and 3′,5′-dichloroaminopterin. J. Med. Chem. 1994, 37, 2167-2174.
25. δ-hemi-phthaloyl-L-ornithine (PT523) modified in the side chain: synthesis and biological evaluation. J. Med. Chem. 1997, 40, 286-299.
26. (a) Allegra, C. J.; Drake, J. C.; Jolivet, J.; Chabner, B. A. Inhibition of phosphoribosyl-aminoimidazolecarboxamide transformylase by methotrexate and dihydrofolic acid polyglutamates. Proc. Natl. Acad. Sci. U.S.A. 1985, 82, 4881-1885.
27. (b) Allegra, C. J.; Chabner, B. A.; Drake, J. C.; Lutz, R.; Rodbard, D.; Jolivet, J. Enhanced inhibition of thymidylate synthase by methotrexate polyglutamates. J. Biol. Chem. 1985, 260, 9720-9726.
28. Rosowsky, A.; Forsch, R. A.; Bader, H.; Freisheim, J. H. Synthesis and in vitro biological activity of new deaza analogues of folic acid, aminopterin, and methotrexate with an L-ornithine side chain. J. Med. Chem. 1991, 34, 1447-1454.
29. 10-methylfolic acid. J. Med. Chem. 1986, 29, 1080-1087.
30. An alternative route to 18 and 19 would be to condense 4-aminobenzoic acid with 2,4-diamino-6-(bromomethyl)pyrido-[2,3-d]pyrimidines; see: Piper, J. R.; Malik, N. D.; Rhee, M. S.; Galivan, J.; Sirotnak, F. M. Synthesis and antifolate evaluation of the 10-propargyl derivatives of 5-deazafolic acid, 5-deazaaminopterin, and 5-methyl-5-deazaaminopterin. J. Med. Chem. 1992, 35, 332-337.
31. Srinivasan, A.; Broom, A. Pyridopyrimidines. 12. Synthesis of 8-deaza analogues of aminopterin and folic acid. J. Org. Chem. 1981, 46, 1777-1781.
32. An improved method of preparation of 26-HBr was subsequently developed; see: Rosowsky, A.; Forsch, R. A.; Queener, S. F. 2,4-Diaminopyrido[3,2-dlpyrimidine inhibitors of dihydrofolate reductase from Pneumocystis carinii and Toxoplasma gondii. J. Med. Chem. 1995, 38, 2615-2620.
33. Davoll, J.; Johnson, A. M. Quinazoline analogues of folic acid. J. Chem. Soc. 1970, 997.
34. Prendergast, N. J.; Delcamp, T. J.; Smith, P. L.; Freisheim, J. H. Expression and site-directed mutagenesis of human dihydrofolate reductase. Biochemistry 1988, 27, 3664-3671.
35. Appleman, J. R.; Prendergast, N.; Delcamp, T. J.; Freisheim, J. H.; Blakley, R. L. Kinetics of the formation and isomerization of methotrexate complexes of recombinant human dihydrofolate reductase. J. Biol. Chem. 1988, 263, 10304-10313.
36. Henderson, P. J. F. A linear equation that describes the steady-state kinetics of enzymes and subcellular particles interacting with tightly bound inhibitors. Biochem. J. 1972, 127, 321-333.
37. Jackson, R. C.; Hart, L. I.; Harrap, K. R. Intrinsic resistance to methotrexate of cultured mammalian cells in relation to the inhibition kinetics of their dihydrofolate reductases. Cancer Res. 1976, 36, 1991-1997.
38. Sirotnak, F. M.; Schmid, F. A.; Otter, G. M.; Piper, J. R.; Montgomery, J. A. Structural design, biochemical properties, and evidence for improved therapeutic activity of 5-alkyl derivatives of 5-deazaminopterin and 5-deazamethotrexate compared to methotrexate in murine tumor models. Cancer Res. 1988, 48, 5686-5691.
39. Rosowsky, A.; Forsch, R. A.; Queener, S. F.; Bertino, J. R. Synthesis of 2,4-diaminopteridines with bulky lipophilic groups at the 6-position as inhibitors of Pneumocystis carinii, Toxoplasma gondii, and mammalian dihydrofolate reductase. Pteridines 1997, 8, 173-187.
40. Chen, G.; Wright, J. E.; Rosowsky, A. Dihydrofolate reductase binding and cellular uptake of nonpolyglutamatable antifolates: correlates of cytotoxicity toward methotrexate-sensitive and -resistant human head and neck squamous carcinoma cells. Mol. Pharmacol. 1995, 48, 758-765.
41. Monks, A.; Scudiero, D.; Skehan, P.; Shoemaker, R.; Paull, K.; Vistica, D.; Hose, C.; Langley, J.; Cronise, P.; Vaigro-Wolff, A.; Gray-Goodrich, M.; Campbell, H.; Mayo, J.; Boyd, M. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J. Natl. Cancer Inst. 1991, 83, 757-766.
42. (a) Stinson, S. F.; Alley, M. C.; Kopp, W. C.; Fiebig, H.-H.; Mullendore, L. A.; Pittman, A. F.; Kenney, S.; Keller, J.; Boyd, M. R. Morphological and immunocytochemical characteristics of human tumor cell lines for use in a disease-oriented anticancer drug screen. Anticancer Res. 1992, 12, 1035-1054.
43. (b) Wu, L.; Smythe, A. M.; Stinson, S. F.; Mullendore, L. A.; Monks, A.; Scudiero, D. A.; Paull, K. D.; Koutsoukos, A. D.; Rubinstein, L. V.; Boyd, M. R.; Schoemaker, R. H. Multidrug-resistant phenotype of disease-oriented panels of human tumor cell lines used for anticancer drug screening. Cancer Res. 1992, 52, 3029-3034.
44. (c) Moscow, J. A.; Connolly, T.; Myers, T. G.; Cheng, C. C.; Paull, K.; Cowan, K. H. Reduced folate carrier gene (RFC1) expression and antifolate resistance in transfected and nonselected cell lines. Int. J. Cancer 1997, 72, 184-190.
45. (d) O'Connor, P. M.; Jackman, J.; Bae, I.; Myers, T. G.; Fan, S.; Mutoh, M.; Scudiero, D. A.; Monks, A.; Sausville, E. A.; Weinstein, J. D.; Friend, S.; Fornace, A. J.; Kohn, K. W. Characterization of the p53 tumor suppressor pathway in cell lines of the NCI anticancer drug screen and correlations with the growth inhibitory potency of 123 anticancer agents. Cancer Res. 1997, 57, 4285-4300.
46. Sirotnak, F. M.; Chello, P. L.; DeGraw, J. I.; Piper, J. R.; Montgomery, J. A. Membrane transport and the molecular basis for selective antitumor action of folate analogues. In Molecular Actions and Targets for Cancer Chemotherapeutic Agents; Sartorelli, A. C., Lazo, J. S., Bertino, J. R., Eds.; Academic Press: New York, 1981; pp 349-384.
47. Kuehl, M.; Brixner, D. I.; Broom, A. D.; Avery, T. L.; Blakley, R. L. Cytotoxicity, uptake, polyglutamate formation, and antileukemic effects of 8-deaza analogues of methotrexate and aminopterin in mice. Cancer Res. 1988, 48, 1481-1488.
48. Susten, S. S.; Hynes, J. B.; Kumar, A.; Freisheim, J. H. Inhibition of dihydrofolate reductase, methotrexate transport, and growth of methotrexate-sensitive and -resistant L1210 leukemia cells in vitro by 5-substituted 2,4-diaminoquinazolines. Biochem. Pharmacol. 1985, 34, 2163-2167.
49. Coll, R. J.; Cesar, D.; Hynes, J. B.; Shane, B. In vitro metabolism of 5,8-dideazafolates and 5,8-dideazaisofolates by mammalian folylpoly-γ-glutamate synthetase. Biochem. Pharmacol. 1991, 42, 833-838.
50. Rosowsky, A.; Freisheim, J. H.; Bader, H.; Forsch, R. A.; Susten, S. S.; Cucchi, C. A.; Frei, E., III. Methotrexate analogues. 25. Chemical and biological studies on the γ-tert-butyl esters of methotrexate and aminopterin. J. Med. Chem. 1985, 28, 660-667.